البلد: أيرلندا
اللغة: الإنجليزية
المصدر: HPRA (Health Products Regulatory Authority)
Gabapentin
PCO Manufacturing Ltd.
N03AX; N03AX12
Gabapentin
600 milligram(s)
Film-coated tablet
Product subject to prescription which may be renewed (B)
Other antiepileptics; gabapentin
Authorised
2009-09-18
_ _ _ _ PACKAGE LEAFLET: INFORMATION FOR THE USER NEURONTIN ® 100 MG, 300 MG & 400 MG HARD CAPSULES 600 MG & 800 MG FILM-COATED TABLETS gabapentin READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. – Keep this leaflet. You may need to read it again. – If you have any further questions, ask your doctor or pharmacist. – This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. – If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Neurontin is and what it is used for 2. What you need to know before you take Neurontin 3. How to take Neurontin 4. Possible side effects 5. How to store Neurontin 6. Contents of the pack and other information 1. WHAT NEURONTIN IS AND WHAT IT IS USED FOR Neurontin belongs to a group of medicines used to treat epilepsy and peripheral neuropathic pain (long lasting pain caused by damage to the nerves). The active substance in Neurontin is gabapentin. NEURONTIN IS USED TO TREAT: – Various forms of epilepsy (seizures that are initially limited to certain parts of the brain, whether the seizure spreads to other parts of the brain or not). The doctor treating you or your child 6 years of age and older will prescribe Neurontin to help treat epilepsy when the current treatment is not fully controlling the condition. You or your child 6 years of age and older should take Neurontin in addition to the current treatment unless told otherwise. Neurontin can also be used on its own to treat adults and children over 12 years of age. – Peripheral neuropathic pain: (long lasting pain caused by damage to the nerves). A variety of different diseases can cause peripheral neuropathic pain (primarily occurring in the legs and/or arms), such as diabetes or shingles. Pain sensations may be described as hot, burning, اقرأ الوثيقة كاملة
Health Products Regulatory Authority 21 January 2020 CRN009FSS Page 1 of 2 SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Neurontin 600 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 600mg film-coated tablet contains 600mg of gabapentin. For the full list of excipients, see section 6.1 3 PHARMACEUTICAL FORM Film-coated tablets _Product imported from UK & Spain:_ White, elliptical film-coated tablets with a bisecting score on both sides and debossed with “NT” and “16” on one side. The tablet can be divided into equal halves. 4 CLINICAL PARTICULARS As per PA 0822/015/004 5 PHARMACOLOGICAL PROPERTIES As per PA 0822/015/004 6 PHARMACEUTICAL PARTICULARS 6.1 LIST OF EXCIPIENTS Each film-coated tablet contains the following excipients: Poloxamer 407 (ethylene oxide and propylene oxide) copovidone maize starch magnesium stearate Film-coating Opadry white YS-1-18111 (hydroxpropylcellulose, talc). Polishing agent: candelilla wax 6.2 INCOMPATIBILITIES Not applicable 6.3 SHELF LIFE The shelf life expiry date for this product shall be the date shown on the container and outer package of the product on the market in the country of origin. Health Products Regulatory Authority 21 January 2020 CRN009FSS Page 2 of 2 6.4 SPECIAL PRECAUTIONS FOR STORAGE Do not store above 25ºC 6.5 NATURE AND CONTENTS OF CONTAINER PVC/PE/PVDC/aluminium foil blister in overlabelled outer Cartons. Pack sizes of 90 or 100 film coated tablets. Not all pack sizes may be marketed. 6.6 SPECIAL PRECAUTIONS FOR DISPOSAL No Special requirements 7 PARALLEL PRODUCT AUTHORISATION HOLDER PCO Manufacturing Ltd. Unit 10, Ashbourne Business Park Rath Ashbourne Co. Meath Ireland 8 PARALLEL PRODUCT AUTHORISATION NUMBER PPA0465/097/004 9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 18 th September 2009 10 DATE OF REVISION OF THE TEXT January 2020 اقرأ الوثيقة كاملة